This Phase I trial is evaluating the effectiveness of a new cancer treatment (PTM-101) in people with boderline resectable or locally advanced pancreatic cancer.
This trial is treating patients with pancreatic ductal adenocarcinoma.
This is a surgical and systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
PanTher Therapeutics and Avania Clinical
PTM-101 is a biodegradable device containing 100mg of paclitaxel. PTM-101 will be placed onto the pancreatic surface overlying the tumour via a laparoscopy. PTM-101 will degrade over approximately 10 weeks.
Recruiting Hospitals Read More